Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Unicycive Therapeutics (UNCY) Leases (2021 - 2026)

Unicycive Therapeutics filings provide 4 years of Leases readings, the most recent being $645000.0 for Q4 2024.

  • On a quarterly basis, Leases fell 15.8% to $645000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $645000.0, a 15.8% decrease, with the full-year FY2024 number at $645000.0, down 15.8% from a year prior.
  • Leases hit $645000.0 in Q4 2024 for Unicycive Therapeutics, down from $772000.0 in the prior quarter.
  • In the past five years, Leases ranged from a high of $997000.0 in Q1 2023 to a low of $152000.0 in Q4 2022.
  • Median Leases over the past 4 years was $645000.0 (2024), compared with a mean of $568000.0.
  • Biggest five-year swings in Leases: plummeted 50.16% in 2022 and later soared 403.95% in 2023.
  • Unicycive Therapeutics' Leases stood at $305000.0 in 2021, then plummeted by 50.16% to $152000.0 in 2022, then soared by 403.95% to $766000.0 in 2023, then dropped by 15.8% to $645000.0 in 2024.
  • The last three reported values for Leases were $645000.0 (Q4 2024), $772000.0 (Q3 2024), and $604000.0 (Q2 2024) per Business Quant data.